AMGN compared with PLX: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

PLXProtalix BioTherapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

PLXProtalix BioTherapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

Q1 FY26±3.9%▼−4.75%×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

PLX

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±12.4%▲+7.82%×0.63

May 13 '26±17.0%▲+1.05%×0.06

= impliedAMGN realized, solidPLX realized, hatchedOne scale, both sides: full bar = 29%× = |realized| ÷ impliedSource: market data

Q1 FY26

±15.2%

▼−20.79%

×1.37

Q3 FY25±28.3%▼−9.81%×0.35

AMGNAmgen Inc

461.49· pre 452.98· delayed

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

PLXProtalix BioTherapeutics, Inc.

2.52· pre 2.52· delayed

Pre-marketNov 6 '26delayed

Mkt cap$202.2MRevenue$20MQ2 FY26Revenue$53MFY25

Compare

Pre-marketNov 6 '26delayed

AMGNAmgen Inc

PLXProtalix BioTherapeutics, Inc.

461.49pre 452.98delayed

Price

2.52pre 2.52delayed

$249.0B

Mkt cap

$202.2M

Q3 FY26$10.4B

Revenue

$20MQ2 FY26

FY25$36.8B

Revenue

$53MFY25

AMGN461.49vsPLX2.52Pre-marketNov 6 '26delayed